These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28686310)

  • 1. Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Correia Guedes L; Reimão S; Paulino P; Nunes RG; Bouça-Machado R; Abreu D; Gonçalves N; Soares T; Fabbri M; Godinho C; Pita Lobo P; Neutel D; Quadri M; Coelho M; Rosa MM; Campos J; Outeiro TF; Sampaio C; Bonifati V; Ferreira JJ
    Mov Disord; 2017 Sep; 32(9):1331-1333. PubMed ID: 28686310
    [No Abstract]   [Full Text] [Related]  

  • 2. Regional nigral neuromelanin degeneration in asymptomatic leucine-rich repeat kinase 2 gene carrier using MRI.
    Gao L; Gaurav R; Ziegner P; Ma J; Sun J; Chen J; Fang J; Fan Y; Bao Y; Zhang D; Chan P; Yang Q; Fan Z; Lehéricy S; Wu T
    Sci Rep; 2024 May; 14(1):10621. PubMed ID: 38729969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased substantia nigra echogenicity in LRRK2 family members without mutations.
    Pullman M; Ortega R; Glickman A; Deik A; Raymond D; Marder K; Giladi N; Bressman S; Hagenah J; Brüggemann N; Saunders-Pullman R
    Mov Disord; 2018 Sep; 33(9):1504-1505. PubMed ID: 30145825
    [No Abstract]   [Full Text] [Related]  

  • 4. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
    Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
    Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging.
    Moon WJ; Park JY; Yun WS; Jeon JY; Moon YS; Kim H; Kwak KC; Lee JM; Han SH
    Korean J Radiol; 2016; 17(5):633-40. PubMed ID: 27587951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers.
    Zhang D; Zhou L; Shi Y; Liu J; Wei H; Tong Q; He H; Wu T
    Mov Disord; 2023 Jan; 38(1):138-142. PubMed ID: 36253640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.
    Xing Y; Sapuan A; Dineen RA; Auer DP
    Mov Disord; 2018 Nov; 33(11):1792-1799. PubMed ID: 30423212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
    Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial for "Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease".
    Reyes SC; Shahraki T; Soman S
    J Magn Reson Imaging; 2024 Aug; 60(2):548-549. PubMed ID: 37915261
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI T
    Lee H; Baek SY; Kim EJ; Huh GY; Lee JH; Cho H
    Neuroimage; 2020 May; 211():116625. PubMed ID: 32058001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.